

腎臓内科学部門

1. Morishita Y, Yoshizawa H, Watanabe M, Ishibashi K, Muto S, Kusano E, Nagata D. siRNAs targeted to Smad4 prevent renal fibrosis in vivo. *Sci Rep* **4**, 6424 (2014)
<https://www.ncbi.nlm.nih.gov/pubmed/25236771>
2. Myojo M, Nagata D, Fujita D, Kiyosue A, Takahashi M, Satonaka H, Morishita Y, Akimoto T, Nagai R, Komuro I, Hirata Y. Telmisartan activates endothelial nitric oxide synthase via Ser1177 phosphorylation in vascular endothelial cells. *PLoS One* **9(5)**, e96948 (2014)
<https://www.ncbi.nlm.nih.gov/pubmed/24827148>
3. Komada T, Usui F, Kawashima A, Kimura H, Karasawa T, Inoue Y, Kobayashi M, Mizushina Y, Kasahara T, Taniguchi S, Muto S, Nagata D, Takahashi M. Role of NLRP3 Inflammasomes for Rhabdomyolysis-induced Acute Kidney Injury. *Sci Rep* 2015 Jun 5;5:10901. doi: 10.1038/srep10901 (2015)
<https://www.ncbi.nlm.nih.gov/pubmed/26045078>
4. Onishi A, Akimoto T, Urabe M, Hirahara I, Muto S, Ozawa K, Nagata D, Kusano E. Attenuation of methylglyoxal-induced peritoneal fibrosis: immunomodulation by interleukin-10. *Lab Invest* **95(12)**, 1353-1362 (2015)
<https://www.ncbi.nlm.nih.gov/pubmed/26367488>
5. Murakami T, Takeda S, Kanazawa H, Ugajin A, Kijima S, Nakamura H, Imai T, Sugase T, Horikoshi R, Kobayashi T, Akimoto T, Saito O, Nagata D. Subclinical growth of an arteriovenous fistula associated with renal biopsy: a case report. *BMC Nephrol* **17(1)**, 81 (2016)
<https://www.ncbi.nlm.nih.gov/pubmed/27406176>
6. Sugase T, Akimoto T, Kubo T, Imai T, Otani-Takei N, Miki T, Takeda S, Nukui A, Muto S, Morita T, Nagata D. Acute kidney injury associated with renal cell carcinoma complicated by renal vein and inferior vena cava involvement. *Intern Med* **55(17)**, 2447-2452 (2016)
[https://www.ncbi.nlm.nih.gov/pubmed/?term=Intern+Med.+2016%3B55\(17\)%3A2447-52](https://www.ncbi.nlm.nih.gov/pubmed/?term=Intern+Med.+2016%3B55(17)%3A2447-52)
7. Igarashi Y, Morishita Y, Yoshizawa H, Imai R, Imai T, Hirahara I, Akimoto T, Ookawara S,

Ishibashi K, Muto S, Nagata D. The association between soluble intercellular adhesion molecule-1 levels in drained dialysate and peritoneal injury in peritoneal dialysis. *Ren Fail* **39(1)**, 392-399 (2017)

<https://www.ncbi.nlm.nih.gov/pubmed/28201944>

8. Imai R, Akimoto T, Kimura T, Kohara M, Shimizu T, Oka K, Shuto M, Asakura M, Nagayama I, Takeda S, Yagisawa T, Muto S, Nagata D. Peritoneal dialysis and retroperitoneal laparoscopic radical nephrectomy: a favorable experience with a patient complicated by renal cell carcinoma. *Clin Med Insights Case Rep* 2017 Dec 10;10:1179547617746362. doi: 10.1177/1179547617746362 (2017)

<https://www.ncbi.nlm.nih.gov/pubmed/?term=Clin+Med+Insights+Case+Rep.+2017%3B10%3A1179547617746362>

9. Kohara M, Masuda T, Shiizaki K, Akimoto T, Watanabe Y, Honma S, Sekiguchi C, Miyazawa Y, Kusano E, Kanda Y, Asano Y, Kuro-O M, Nagata D. Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease. *PLoS One* **12(6)**, e0178971 (2017)

<https://www.ncbi.nlm.nih.gov/pubmed/28582462>

10. Iwazu Y, Muto S, Ioka T, Watanabe Y, Iwazu K, Kusano E, Nagata D. Multiple sclerosis drug fingolimod induces thrombotic microangiopathy in deoxycorticosterone acetate/salt hypertension. *Hypertension* **72(3)**, 776-784 (2018)

<https://www.ncbi.nlm.nih.gov/pubmed/30354753>

11. Masuda T, Watanabe Y, Fukuda K, Watanabe M, Onishi A, Ohara K, Imai T, Koepsell H, Muto S, Vallon V, Nagata D. Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat. *Am J Physiol Renal Physiol* **315(3)**, F653-F664 (2018)

<https://www.ncbi.nlm.nih.gov/pubmed/29790389>

12. Murakami T, Akimoto T, Okada M, Hishida E, Sugase T, Miki A, Kohara M, Yoshizawa H, Masuda T, Kobayashi T, Saito O, Muto S, Nagata D. Valacyclovir neurotoxicity and nephrotoxicity in an elderly patient complicated by hyponatremia. *Drug Target Insights* 2018 Jun 25;12:1177392818782899. doi: 10.1177/1177392818782899 (2018)

<https://www.ncbi.nlm.nih.gov/pubmed/30013310>

13. Murakami T, Akimoto T, Yamazaki T, Yoshizawa H, Okada M, Miki A, Nakagawa S, Ohara K, Sugase T, Masuda T, Kobayashi T, Saito O, Muto S, Nagata D. Hemolytic uremic syndrome: An increasingly recognized public health problem. *Clin Med Insights Case Rep* 2018 Jul 3;11:1179547618785137. doi: 10.1177/1179547618785137 (2018)
<https://www.ncbi.nlm.nih.gov/pubmed/30083060>
14. Nagayama I, Akimoto T, Ono Y, Ueda Y, Nagata D. Remission of nephrotic syndrome after surgical intervention for bronchogenic carcinoma: the 10-year follow-up of a patient with membranous nephropathy. *Int Med Case Rep J* 11, 167-171 (2018)
<https://www.ncbi.nlm.nih.gov/pubmed/30104905>
15. Ohara K, Masuda T, Murakami T, Imai T, Yoshizawa H, Nakagawa S, Okada M, Miki A, Myoga A, Sugase T, Sekiguchi C, Miyazawa Y, Maeshima A, Akimoto T, Saito O, Muto S, Nagata D. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan. *Nephrology (Carlton)* 2018 Dec 22. doi: 10.1111/nep.13552 (2018)
<https://www.ncbi.nlm.nih.gov/pubmed/30578654>
16. Oka K, Sugase T, Akimoto T, Murakami T, Nagayama I, Kaneko M, Asakura M, Ohara K, Saito O, Nagata D. Kartagener syndrome complicated by immunoglobulin A nephropathy. *Int Med Case Rep J* 11, 359-362 (2018)
<https://www.ncbi.nlm.nih.gov/pubmed/30573994>
17. Akimoto T, Muto S, Kutsuwada T, Kutsuwada K, Nagata D. Peritoneal dialysis and malignancy: An experience with a patient complicated by gastric carcinoma. *Clin Med Insights Case Re* 2019 Mar 12;12:1179547619835176. doi: 10.1177/1179547619835176 (2019)
<https://www.ncbi.nlm.nih.gov/pubmed/30886527>
18. Masuda T, Ohara K, Nagayama I, Matsuoka R, Murakami T, Nakagawa S, Oka K, Asakura M, Igarashi Y, Fukaya Y, Miyazawa Y, Maeshima A, Akimoto T, Saito O, Nagata D. Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients. *Int Urol Nephrol* 2019 Jun 3. doi: 10.1007/s11255-019-02180-8 (2019)
<https://www.ncbi.nlm.nih.gov/pubmed/31161520>